SGLT-2 inhibitors canagliflozin, empagliflozin, and dapagliflozin showed overall comparable effectiveness on cardiovascular outcomes in T2D.

No randomized clinical trials have directly compared empagliflozin with dapagliflozin for type 2 diabetes, so investigators conducted a large comparative effectiveness study examining kidney outcomes.

A team of scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC), working in collaboration with ...

“Our data suggest SGLT2 inhibition as a safe strategy to prevent kidney stone recurrence in patients with kidney stones ,” Dr Fuster’s team concluded. Other study findings indicate the empagliflozin ...

Experts are now calling for NHS guidance - which does not recommend managing diabetes with different drugs depending on age - ...

The tiny bits of plastic pollution that make their way from the environment into our bodies accumulate at much higher ...

Kolkata: Prices of 42 medicines, including those used for day-to-day consumption, are likely to change following an order by ...

In keeping with current guidelines, either empagliflozin or dapagliflozin can be used for preventing AKI and CKD in patients with type 2 diabetes. Empagliflozin and dapagliflozin are equally ...

CardioOncology, shows that administration of the SGLT2 inhibitor empagliflozin to pigs receiving anthracyclines preserves ...

A team of scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC), working in collaboration with ...

A team of scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC), working in collaboration with international partners, has designed a strategy for preventing the cardiotoxic ...

Compared with people who had type 2 diabetes treated with empagliflozin (Jardiance), peers on canagliflozin (Invokana; HR 0.98, 95% CI 0.91-1.05) or dapagliflozin (Farxiga; HR 0.95, 95% CI 0.89-1. ...